Trial Outcomes & Findings for Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome (NCT NCT01743001)

NCT ID: NCT01743001

Last Updated: 2018-02-23

Results Overview

The purpose of the six minute walk is to test exercise tolerance and capacity. The test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

226 participants

Primary outcome timeframe

From baseline to Week 16

Results posted on

2018-02-23

Participant Flow

The study was conducted at 71 sites in 26 countries (geographical regions: Asia-Pacific, Eastern Europe, Latin America, North America, Western Europe including Israel and Turkey, and South Africa), of which 55 sites in 21 countries randomized subjects.

The screening period lasted a maximum of 30 days from Visit 1 up to Randomization (Visit 2). A total of 319 subjects were screened and 226 subjects were randomized to macitentan 10 mg and placebo.

Participant milestones

Participant milestones
Measure
Macitentan
Subjects receive macitentan 10 mg, oral tablet, to be taken once daily
Placebo
Subjects receive macitentan-matching placebo, oral tablet, to be taken once daily
Overall Study
STARTED
114
112
Overall Study
COMPLETED
111
112
Overall Study
NOT COMPLETED
3
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Macitentan
Subjects receive macitentan 10 mg, oral tablet, to be taken once daily
Placebo
Subjects receive macitentan-matching placebo, oral tablet, to be taken once daily
Overall Study
Physician Decision
1
0
Overall Study
Pregnancy
1
0
Overall Study
Death
1
0

Baseline Characteristics

Per protocol patients in WHO functional class I were excluded.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Macitentan
n=114 Participants
Subjects receive macitentan 10 mg, oral tablet, to be taken once daily
Placebo
n=112 Participants
Subjects receive macitentan-matching placebo, oral tablet, to be taken once daily
Total
n=226 Participants
Total of all reporting groups
Age, Continuous
33.0 Years
n=99 Participants
31.0 Years
n=107 Participants
32.0 Years
n=206 Participants
Age, Customized
12 - 17 years
13 Participants
n=99 Participants
2 Participants
n=107 Participants
15 Participants
n=206 Participants
Age, Customized
18 - 55 years
90 Participants
n=99 Participants
105 Participants
n=107 Participants
195 Participants
n=206 Participants
Age, Customized
≥ 56 years
11 Participants
n=99 Participants
5 Participants
n=107 Participants
16 Participants
n=206 Participants
Sex: Female, Male
Female
82 Participants
n=99 Participants
68 Participants
n=107 Participants
150 Participants
n=206 Participants
Sex: Female, Male
Male
32 Participants
n=99 Participants
44 Participants
n=107 Participants
76 Participants
n=206 Participants
Region of Enrollment
Asia-Pacific
47 Participants
n=99 Participants
44 Participants
n=107 Participants
91 Participants
n=206 Participants
Region of Enrollment
Eastern Europe
25 Participants
n=99 Participants
27 Participants
n=107 Participants
52 Participants
n=206 Participants
Region of Enrollment
Latin America
19 Participants
n=99 Participants
18 Participants
n=107 Participants
37 Participants
n=206 Participants
Region of Enrollment
North America
2 Participants
n=99 Participants
5 Participants
n=107 Participants
7 Participants
n=206 Participants
Region of Enrollment
Western Europe - Israel
21 Participants
n=99 Participants
18 Participants
n=107 Participants
39 Participants
n=206 Participants
Body Mass Index (BMI)
21.15 kg/m^2
n=99 Participants
21.55 kg/m^2
n=107 Participants
21.35 kg/m^2
n=206 Participants
WHO functional class
class I
0 Participants
n=99 Participants • Per protocol patients in WHO functional class I were excluded.
0 Participants
n=107 Participants • Per protocol patients in WHO functional class I were excluded.
0 Participants
n=206 Participants • Per protocol patients in WHO functional class I were excluded.
WHO functional class
class II
69 Participants
n=99 Participants • Per protocol patients in WHO functional class I were excluded.
66 Participants
n=107 Participants • Per protocol patients in WHO functional class I were excluded.
135 Participants
n=206 Participants • Per protocol patients in WHO functional class I were excluded.
WHO functional class
class III
45 Participants
n=99 Participants • Per protocol patients in WHO functional class I were excluded.
46 Participants
n=107 Participants • Per protocol patients in WHO functional class I were excluded.
91 Participants
n=206 Participants • Per protocol patients in WHO functional class I were excluded.
WHO functional class
class IV
0 Participants
n=99 Participants • Per protocol patients in WHO functional class I were excluded.
0 Participants
n=107 Participants • Per protocol patients in WHO functional class I were excluded.
0 Participants
n=206 Participants • Per protocol patients in WHO functional class I were excluded.

PRIMARY outcome

Timeframe: From baseline to Week 16

Population: Full analysis set: The analysis was performed on the full analysis set (FAS), i.e., all randomized subjects in the treatment group to which they were randomized and by imputing missing values at Week 16 according to pre-defined rules.

The purpose of the six minute walk is to test exercise tolerance and capacity. The test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.

Outcome measures

Outcome measures
Measure
Macitentan
n=114 Participants
Subjects receive macitentan 10 mg, oral tablet, to be taken once daily
Placebo
n=112 Participants
Subjects receive macitentan-matching placebo, oral tablet, to be taken once daily
Change From Baseline to Week 16 in Exercise Capacity, as Measured by 6-minute Walk Distance (6MWD)
6MWD at baseline
368.7 meter
Standard Deviation 74.5
380.3 meter
Standard Deviation 76.3
Change From Baseline to Week 16 in Exercise Capacity, as Measured by 6-minute Walk Distance (6MWD)
6MWD at Week 16
387.1 meter
Standard Deviation 101.8
399.9 meter
Standard Deviation 79.5
Change From Baseline to Week 16 in Exercise Capacity, as Measured by 6-minute Walk Distance (6MWD)
Change in 6MWD from baseline to Week 16
18.3 meter
Standard Deviation 84.4
19.7 meter
Standard Deviation 53.0

SECONDARY outcome

Timeframe: From baseline to Week 16

Population: Full analysis set: The analysis was performed on the full analysis set (FAS), i.e., all randomized subjects in the treatment group to which they were randomized and by imputing missing values at Week 16 according to pre-defined rules.

A shift in WHO functional classes is considered an 'improvement' when shifting to a lower class (e.g. from class III to class II) or a 'worsening' when shifting to a higher class (e.g. from class III to class IV). Definition of functional classes as follows - Class I: no symptoms with exercise or at rest. Class II: No symptoms at rest but uncomfortable and short of breath with normal activity such as climbing a flight of stairs, grocery shopping, or making the bed. Class III: May not have symptoms at rest but activities greatly limited by shortness of breath, fatigue, or near fainting (e.g. doing normal chores around the house, have to take breaks while doing activities of daily living). Class IV: Symptoms at rest and severe symptoms with any activity. Most patients also have edema in the feet and ankles as result of right heart failure.

Outcome measures

Outcome measures
Measure
Macitentan
n=114 Participants
Subjects receive macitentan 10 mg, oral tablet, to be taken once daily
Placebo
n=112 Participants
Subjects receive macitentan-matching placebo, oral tablet, to be taken once daily
Change From Baseline to Week 16 in WHO Functional Class
WHO functional class 1 at Week 16
3 Participants
1 Participants
Change From Baseline to Week 16 in WHO Functional Class
WHO functional class 2 at Week 16
72 Participants
79 Participants
Change From Baseline to Week 16 in WHO Functional Class
WHO functional class 3 at Week 16
38 Participants
32 Participants
Change From Baseline to Week 16 in WHO Functional Class
WHO functional class 4 at Week 16
1 Participants
0 Participants
Change From Baseline to Week 16 in WHO Functional Class
Unchanged from baseline to Week 16
103 Participants
95 Participants
Change From Baseline to Week 16 in WHO Functional Class
Improvement from baseline to Week 16
10 Participants
16 Participants
Change From Baseline to Week 16 in WHO Functional Class
Worsening from baseline to Week 16
1 Participants
1 Participants

SECONDARY outcome

Timeframe: From baseline to Week 16

Population: Full analysis set: The analysis was performed on the full analysis set (FAS), i.e., all randomized subjects in the treatment group to which they were randomized and by imputing missing values at Week 16 according to pre-defined rules.

This outcome measures the difference in the Borg dyspnea index collected at the end of the 6-minute walk test (6MWT) at Week 16 compared to baseline. The Borg dyspnea index rates the severity of dyspnea (difficult or labored breathing) on a scale from 0 ('Nothing at all') to 10 ('Very, very severe - maximal'). A decrease in the Borg dyspnea index indicates an improvement.

Outcome measures

Outcome measures
Measure
Macitentan
n=114 Participants
Subjects receive macitentan 10 mg, oral tablet, to be taken once daily
Placebo
n=112 Participants
Subjects receive macitentan-matching placebo, oral tablet, to be taken once daily
Change From Baseline to Week 16 in Dyspnea, Assessed by the Borg Dyspnea Index
Borg dyspnea index score at baseline
3.00 Score on a scale
Standard Deviation 1.95
2.94 Score on a scale
Standard Deviation 1.88
Change From Baseline to Week 16 in Dyspnea, Assessed by the Borg Dyspnea Index
Borg dyspnea index score at Week 16
2.78 Score on a scale
Standard Deviation 2.10
2.66 Score on a scale
Standard Deviation 1.64
Change From Baseline to Week 16 in Dyspnea, Assessed by the Borg Dyspnea Index
Change from baseline to Week 16
-0.22 Score on a scale
Standard Deviation 1.56
-0.29 Score on a scale
Standard Deviation 1.50

SECONDARY outcome

Timeframe: From baseline to Week 16

Population: Full analysis set (excluding children \<14 years of age and Down Syndrome subjects)

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of the functional health and well-being scores (i.e., physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health), as well as psychometrically based physical and mental health summary measures and a preference-based health utility (health rated as much better now than one year ago to much worse now than one year ago). It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group. For each of the domains and scores that the SF36 measures an aggregate percentage score is produced. The percentage scores range from 0% (lowest or worst possible level of functioning) to 100% (highest or best possible level of functioning). A higher score for the individual domains and summary component scores indicates a better condition of the subject.

Outcome measures

Outcome measures
Measure
Macitentan
n=101 Participants
Subjects receive macitentan 10 mg, oral tablet, to be taken once daily
Placebo
n=99 Participants
Subjects receive macitentan-matching placebo, oral tablet, to be taken once daily
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: physical functioning at baseline
51.9 Score on a scale
Standard Deviation 21.8
52.7 Score on a scale
Standard Deviation 22.4
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: physical functioning at Week 16
56.4 Score on a scale
Standard Deviation 21.9
58.0 Score on a scale
Standard Deviation 19.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in physical functioning (domain score)
4.6 Score on a scale
Standard Deviation 16.5
5.3 Score on a scale
Standard Deviation 15.4
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: role-physical at baseline
46.2 Score on a scale
Standard Deviation 25.5
48.4 Score on a scale
Standard Deviation 27.9
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: role-physical at Week 16
52.8 Score on a scale
Standard Deviation 25.5
55.9 Score on a scale
Standard Deviation 25.3
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in role-physical (domain score)
6.6 Score on a scale
Standard Deviation 20.1
7.4 Score on a scale
Standard Deviation 22.1
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: pain index at baseline
61.7 Score on a scale
Standard Deviation 23.0
64.6 Score on a scale
Standard Deviation 24.6
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: pain index at Week 16
65.2 Score on a scale
Standard Deviation 23.6
66.2 Score on a scale
Standard Deviation 24.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in pain index (domain score)
3.5 Score on a scale
Standard Deviation 22.1
1.6 Score on a scale
Standard Deviation 27.1
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score:general health perceptions baseline
36.1 Score on a scale
Standard Deviation 21.0
37.2 Score on a scale
Standard Deviation 19.8
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score:general health perceptions at Week 16
40.3 Score on a scale
Standard Deviation 22.7
37.6 Score on a scale
Standard Deviation 20.3
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in general health perceptions(domain score)
4.2 Score on a scale
Standard Deviation 16.4
0.5 Score on a scale
Standard Deviation 15.5
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: vitality at baseline
49.0 Score on a scale
Standard Deviation 22.1
51.9 Score on a scale
Standard Deviation 21.5
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: vitality at Week 16
56.1 Score on a scale
Standard Deviation 19.8
56.3 Score on a scale
Standard Deviation 17.5
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in vitality (domain score)
7.1 Score on a scale
Standard Deviation 18.3
4.4 Score on a scale
Standard Deviation 18.2
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: social functioning at baseline
64.7 Score on a scale
Standard Deviation 26.8
66.9 Score on a scale
Standard Deviation 25.0
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: social functioning at Week 16
66.6 Score on a scale
Standard Deviation 25.8
69.2 Score on a scale
Standard Deviation 23.5
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in social functioning (domain score)
1.9 Score on a scale
Standard Deviation 23.0
2.3 Score on a scale
Standard Deviation 24.5
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: role-emotional at baseline
61.6 Score on a scale
Standard Deviation 27.4
61.3 Score on a scale
Standard Deviation 28.8
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: role-emotional at Week 16
63.3 Score on a scale
Standard Deviation 26.8
66.0 Score on a scale
Standard Deviation 25.6
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in role-emotional (domain score)
1.7 Score on a scale
Standard Deviation 22.8
4.7 Score on a scale
Standard Deviation 25.0
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: mental health index at baseline
63.8 Score on a scale
Standard Deviation 21.1
64.0 Score on a scale
Standard Deviation 20.5
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Domain score: mental health index at Week 16
65.7 Score on a scale
Standard Deviation 18.9
67.7 Score on a scale
Standard Deviation 20.6
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in mental health index (domain score)
1.9 Score on a scale
Standard Deviation 16.1
3.7 Score on a scale
Standard Deviation 16.6
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: physical functioning at baseline
36.8 Score on a scale
Standard Deviation 9.2
37.1 Score on a scale
Standard Deviation 9.4
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: physical functioning at Week 16
38.7 Score on a scale
Standard Deviation 9.2
39.3 Score on a scale
Standard Deviation 8.3
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in physical functioning (norm-based)
1.9 Score on a scale
Standard Deviation 6.9
2.2 Score on a scale
Standard Deviation 6.5
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: role-physical at baseline
35.8 Score on a scale
Standard Deviation 10.0
36.6 Score on a scale
Standard Deviation 10.9
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: role-physical at Week 16
38.4 Score on a scale
Standard Deviation 10.0
39.6 Score on a scale
Standard Deviation 9.9
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in role-physical (norm-based)
2.6 Score on a scale
Standard Deviation 7.9
2.9 Score on a scale
Standard Deviation 8.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: pain index at baseline
45.9 Score on a scale
Standard Deviation 9.7
47.2 Score on a scale
Standard Deviation 10.4
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: pain index at Week 16
47.4 Score on a scale
Standard Deviation 10.0
47.8 Score on a scale
Standard Deviation 10.4
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in pain index (norm-based)
1.5 Score on a scale
Standard Deviation 9.3
0.7 Score on a scale
Standard Deviation 11.5
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: general health perceptions at baseline
33.4 Score on a scale
Standard Deviation 10.0
33.9 Score on a scale
Standard Deviation 9.4
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: general health perceptions at Week 16
35.4 Score on a scale
Standard Deviation 10.8
34.2 Score on a scale
Standard Deviation 9.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in general health perceptions (norm-based)
2.0 Score on a scale
Standard Deviation 7.8
0.2 Score on a scale
Standard Deviation 7.4
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: vitality at baseline
45.4 Score on a scale
Standard Deviation 11.1
46.8 Score on a scale
Standard Deviation 10.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: vitality at Week 16
48.9 Score on a scale
Standard Deviation 9.9
49.0 Score on a scale
Standard Deviation 8.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in vitality (norm-based)
3.6 Score on a scale
Standard Deviation 9.1
2.2 Score on a scale
Standard Deviation 9.1
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: social functioning at baseline
41.5 Score on a scale
Standard Deviation 11.7
42.4 Score on a scale
Standard Deviation 10.9
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: social functioning at Week 16
42.3 Score on a scale
Standard Deviation 11.3
43.4 Score on a scale
Standard Deviation 10.3
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in social functioning (norm-based)
0.8 Score on a scale
Standard Deviation 10.0
1.0 Score on a scale
Standard Deviation 10.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: role-emotional at baseline
37.9 Score on a scale
Standard Deviation 12.8
37.8 Score on a scale
Standard Deviation 13.4
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: role-emotional at Week 16
38.8 Score on a scale
Standard Deviation 12.5
40.0 Score on a scale
Standard Deviation 11.9
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in role-emotional (norm-based)
0.8 Score on a scale
Standard Deviation 10.6
2.2 Score on a scale
Standard Deviation 11.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: mental health index at baseline
43.7 Score on a scale
Standard Deviation 11.9
43.8 Score on a scale
Standard Deviation 11.6
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Norm-based: mental health index at Week 16
44.8 Score on a scale
Standard Deviation 10.6
45.9 Score on a scale
Standard Deviation 11.6
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in mental health index (norm-based)
1.1 Score on a scale
Standard Deviation 9.1
2.1 Score on a scale
Standard Deviation 9.3
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Physical component summary score at baseline
37.6 Score on a scale
Standard Deviation 7.5
38.6 Score on a scale
Standard Deviation 8.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Physical component summary score at Week 16
40.0 Score on a scale
Standard Deviation 8.4
40.0 Score on a scale
Standard Deviation 7.7
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in physical component summary score
2.4 Score on a scale
Standard Deviation 6.4
1.4 Score on a scale
Standard Deviation 6.5
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Mental component summary score at baseline
43.8 Score on a scale
Standard Deviation 12.4
44.1 Score on a scale
Standard Deviation 12.1
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Mental component summary score at Week 16
44.7 Score on a scale
Standard Deviation 11.7
45.9 Score on a scale
Standard Deviation 10.9
Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire
Change in mental component summary score
1.0 Score on a scale
Standard Deviation 9.3
1.8 Score on a scale
Standard Deviation 9.3

Adverse Events

Macitentan

Serious events: 7 serious events
Other events: 31 other events
Deaths: 1 deaths

Placebo

Serious events: 2 serious events
Other events: 30 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Macitentan
n=114 participants at risk
Subjects receive macitentan 10 mg orally to be taken once daily. 114 subjects were exposed to Macitentan 10 mg for 15.93 weeks on average.
Placebo
n=112 participants at risk
Subjects receive macitentan-matching placebo orally to be taken once daily. 112 subjects were exposed to placebo for 15.96 weeks on average.
Renal and urinary disorders
Acute kidney injury
0.88%
1/114 • Number of events 1 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.00%
0/112 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Cardiac disorders
Atrial fibrillation
0.88%
1/114 • Number of events 1 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.89%
1/112 • Number of events 2 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Cardiac disorders
Cardiac failure chronic
0.00%
0/114 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.89%
1/112 • Number of events 1 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Nervous system disorders
Dizziness
0.88%
1/114 • Number of events 1 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.00%
0/112 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Infections and infestations
Endocarditis
0.88%
1/114 • Number of events 1 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.00%
0/112 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Infections and infestations
Pneumonia
1.8%
2/114 • Number of events 2 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.00%
0/112 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Respiratory, thoracic and mediastinal disorders
Respiratory failure
0.88%
1/114 • Number of events 1 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.00%
0/112 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Cardiac disorders
Right ventricular failure
2.6%
3/114 • Number of events 4 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.00%
0/112 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Infections and infestations
Septic shock
0.88%
1/114 • Number of events 1 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.00%
0/112 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Nervous system disorders
Transient ischaemic attack
0.88%
1/114 • Number of events 1 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
0.00%
0/112 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.

Other adverse events

Other adverse events
Measure
Macitentan
n=114 participants at risk
Subjects receive macitentan 10 mg orally to be taken once daily. 114 subjects were exposed to Macitentan 10 mg for 15.93 weeks on average.
Placebo
n=112 participants at risk
Subjects receive macitentan-matching placebo orally to be taken once daily. 112 subjects were exposed to placebo for 15.96 weeks on average.
Infections and infestations
Bronchitis
5.3%
6/114 • Number of events 6 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
2.7%
3/112 • Number of events 3 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Respiratory, thoracic and mediastinal disorders
Haemoptysis
0.00%
0/114 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
5.4%
6/112 • Number of events 8 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Nervous system disorders
Headache
11.4%
13/114 • Number of events 15 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
4.5%
5/112 • Number of events 5 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Infections and infestations
Nasopharyngitis
2.6%
3/114 • Number of events 4 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
12.5%
14/112 • Number of events 16 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
Infections and infestations
Upper respiratory tract infection
9.6%
11/114 • Number of events 12 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.
6.2%
7/112 • Number of events 10 • A safety follow-up visit was required 30 days after end of treatment period at Week 16. Subjects who prematurely discontinued treatment prior to Week 16 were required to perform a premature end-of-treatment visit no later than 7 days after last dose of study treatment and then followed by the 30 day safety follow-up visit.

Additional Information

Clinical Trial Disclosure Desk

Actelion Pharmaceuticals Ltd

Results disclosure agreements

  • Principal investigator is a sponsor employee Any study-related publication written independently by investigators must be submitted to Actelion for review at least 60 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.
  • Publication restrictions are in place

Restriction type: OTHER